Thursday, 25 April 2024
Biondvax Pharmaceuticals Ltd.
NASDAQ : BVXV
0.6100 14 Oct 22 00:00 | Change: 0.01 | Open: 0.6100 | High: 0.6400 | Ask: 0.0000 | Volume: 37,000 |
Change(%): 1.60 | Prev: 0.6199 | Low: 0.5900 | Bid: 0.0000 | Avg vol: 0 |
09:37 | 24/2/18
Frisco Fastball
BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) has risen 97.97% since February 23, 2017 and is uptrending. It has outperformed by 81.27% the S&P500.
more»
More notable recent BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) news were published by: Benzinga.com which released: “25 Stocks Moving In Wednesday's Pre-Market Session” on September 13, 2017, also Benzinga.
more»
More notable recent BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) news were published by: Benzinga.com which released: “28 Stocks Moving In Monday's Pre-Market Session” on October 09, 2017, also Benzinga.
more»
23:38 | 15/1/18
Investing.com
Over 2017 BiondVax Pharmaceuticals Ltd ADR (NASDAQ:BVXV) crystallised its late-stage development plans for lead asset M-001, a potentially universal influenza vaccine.
more»
02:52 | 3/1/18
Markets Insider
NESS ZIONA, Israel, Jan. 2, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (TASE: BVXV), developer of M-001, the Universal Flu Vaccine candidate currently in preparation for a Phase 3 clinical trial, announced today that one of its ...
more»
There are currently no comments on this topic.
Be the first person to Add a Comment...
You must be a registered user to post a comment: REGISTER NOW
If you are already registered, please LOGIN NOW
|
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |